E Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
Other funds holding CRVS
E Fund Management's CRVS Position: Q3 2026 in Review
E Fund Management increased its Corvus Pharmaceuticals (CRVS) stake by 536% in Q3 2026, buying an estimated $858K and bringing the position to 73,085 shares worth $842K. The position accounts for 0.02% of the portfolio, ranked #209.
E Fund Management first reported a position in CRVS in Q1 2026 and has held it in 3 quarters since. 177 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.
- E Fund Management held 73,085 shares of Corvus Pharmaceuticals worth $842K as of Q3 2026.
- E Fund Management bought 61,594 Corvus Pharmaceuticals shares in Q3 2026, an estimated $858K.
- Corvus Pharmaceuticals made up 0.02% of E Fund Management's portfolio in Q3 2026, its #209 holding.
- E Fund Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 177 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.
Based on E Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.